Company intelligence / Profile preview
Huadong Medicine
Hangzhou, Zhejiang, Chinaeastchinapharm.com ↗
- Ownership
- Public · 000963
- Employees
- ~8000
- Development stage
- Commercial
01
Overview
Leading Chinese pharma with commercialized drugs in diabetes/organ transplant and multiple clinical-stage assets including oral GLP-1 agonist HDM1002 (Phase II) and PARP inhibitor Senaparib (NDA filed). Maintains broad pipeline across metabolic disorders, oncology and immunology.
- Therapeutic areas
- OncologyEndocrinologyImmunology
- Modalities
- Small molecules(Biosimilars)(Antibody-drug conjugates)(Bispecific antibodies)
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Partnerships
IMPACT Therapeutics(Senaparib promotion)[7]IMBiologics(autoimmune drug candidates)[9]
04
Financials
- Market cap
- $7.3B
- Total revenue
- $6.5B
- Enterprise value
- $7.5B
Beyond the preview
Go deeper on Huadong Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huadong Medicine.